thiotepa has been researched along with Rhabdomyosarcoma in 8 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Rhabdomyosarcoma: A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "From June 1997 to November 1999, 28 SRCT patients (median age, 26 years; 14 peripheral primitive neuroectodermal tumors [pPNETs], seven rhabdomyosarcomas [RMSs], and seven desmoplastic small round-cell tumors [DSRCTs]) received induction chemotherapy with ifosfamide, epirubicin, and vincristine followed by HD-CT." | 5.10 | High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. ( Alloisio, M; Balzarotti, M; Bertuzzi, A; Castagna, L; Compasso, S; Nozza, A; Quagliuolo, V; Santoro, A; Siracusano, L; Soto Parra, H, 2002) |
| " Whenever one patient at one dosage level showed a grade III or grade IV reversible toxicity, additional patients were admitted (one by one) up to a maximum number of 6." | 2.69 | Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors. ( Bella, S; Burnelli, R; Garaventa, A; Locatelli, F; Melchionda, F; Paolucci, G; Pession, A; Prete, A, 1999) |
| "ThioTEPA was administered intravenously every three weeks, at a dose of 65 mg/m2." | 2.68 | A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study. ( Balis, FM; Bleyer, WA; Broxson, E; Geyer, JR; Heideman, R; Krailo, MD; Poplack, D; Sato, JK, 1996) |
| "Patients with infratentorial brain metastases of highly malignant pediatric non-epithelial tumors are in a severe clinical state, but still can have longer and useful lives with aggressive multimodal treatments combined with radical surgical resection." | 1.37 | Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports. ( Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Osawa, S | 1 |
| Kumabe, T | 1 |
| Saito, R | 1 |
| Sonoda, Y | 1 |
| Niizuma, H | 1 |
| Watanabe, M | 1 |
| Tominaga, T | 1 |
| Geyer, JR | 1 |
| Balis, FM | 1 |
| Krailo, MD | 1 |
| Heideman, R | 1 |
| Broxson, E | 1 |
| Sato, JK | 1 |
| Poplack, D | 1 |
| Bleyer, WA | 1 |
| Walterhouse, DO | 1 |
| Hoover, ML | 1 |
| Marymont, MA | 1 |
| Kletzel, M | 1 |
| Pession, A | 1 |
| Prete, A | 1 |
| Locatelli, F | 1 |
| Bella, S | 1 |
| Melchionda, F | 1 |
| Garaventa, A | 1 |
| Burnelli, R | 1 |
| Paolucci, G | 1 |
| Bertuzzi, A | 1 |
| Castagna, L | 1 |
| Nozza, A | 1 |
| Quagliuolo, V | 1 |
| Siracusano, L | 1 |
| Balzarotti, M | 1 |
| Compasso, S | 1 |
| Alloisio, M | 1 |
| Soto Parra, H | 1 |
| Santoro, A | 1 |
| Livingston, RB | 1 |
| Swierzowa, J | 1 |
| Mahaley, MS | 1 |
| Woodhall, B | 1 |
1 review available for thiotepa and Rhabdomyosarcoma
| Article | Year |
|---|---|
Chemotherapy of solid tumors. Recent advances.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Bronchogenic; Carcinom | 1976 |
3 trials available for thiotepa and Rhabdomyosarcoma
| Article | Year |
|---|---|
A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Humans; Neoplasms; Neuroectode | 1996 |
Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1999 |
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophos | 2002 |
4 other studies available for thiotepa and Rhabdomyosarcoma
| Article | Year |
|---|---|
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin | 2011 |
High-dose chemotherapy followed by peripheral blood stem cell rescue for metastatic rhabdomyosarcoma: the experience at Chicago Children's Memorial Hospital.
Topics: Adolescent; Bone Marrow Neoplasms; Carboplatin; Child; Combined Modality Therapy; Cyclophosphamide; | 1999 |
Clinical evaluation of patients treated for rhabdomyosarcoma.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Evaluation Studies as Topic; Fem | 1972 |
Regional chemotherapeutic perfusion and infusion of brain and face tumors.
Topics: Adenocarcinoma; Ameloblastoma; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carcinoma; Carci | 1967 |